Jacobsen J S, Muenkel H A, Blume A J, Vitek M P
Central Nervous System Biological Research Department, American Cyanamid Company, Pearl River, NY 10965.
Neurobiol Aging. 1991 Sep-Oct;12(5):575-83. doi: 10.1016/0197-4580(91)90089-3.
Using an S1 nuclease protection assay, we have identified a novel "variant" Amyloid Precursor Protein (APP) RNA in human brain which is 3-6-fold more abundant than APP-770, but less abundant than APP-751 or APP-695. This variant, referred to as amyloid precursor-related protein 365 (APRP-365), is not detected in mouse and rat brain RNAs. A 1.6 kilo-basepair cDNA clone corresponding to this variant APP RNA predicts the existence of a 365 amino acid protein that is similar to the amino-terminal end of APP-770 but lacks the beta-amyloid peptide and any hydrophobic transmembrane spanning domains. In a modified polymerase chain reaction (PCR), we used amplification of reverse transcribed mRNA to confirm and extend our S1 observations. Together, the features of APRP-365 suggest that the human variant is a soluble protein containing a Kunitz protease inhibitor domain.
利用S1核酸酶保护分析,我们在人脑中鉴定出一种新型“变体”淀粉样前体蛋白(APP)RNA,其丰度比APP - 770高3至6倍,但低于APP - 751或APP - 695。这种变体被称为淀粉样前体相关蛋白365(APRP - 365),在小鼠和大鼠脑RNA中未检测到。与这种变体APP RNA相对应的一个1.6千碱基对的cDNA克隆预测存在一种365个氨基酸的蛋白质,它与APP - 770的氨基末端相似,但缺乏β-淀粉样肽和任何疏水跨膜结构域。在改良的聚合酶链反应(PCR)中,我们使用逆转录mRNA的扩增来证实并扩展我们的S1观察结果。总之,APRP - 365的特征表明这种人类变体是一种含有Kunitz蛋白酶抑制剂结构域的可溶性蛋白。